Role of the Early-Life Microbiome in the Development of Food Allergy

Food allergies (FA) affect millions of children worldwide, often emerging during the critical early-life period when the gut microbiota and the immune system codevelop. This review examines the current evidence linking infant gut microbiome development to FA risk, gaps in current knowledge, and future directions. Substantial evidence from animal models and human studies implicates the developing gut microbiome in shaping immune tolerance to food antigens through various mechanisms. Early-life gut microbiome dysbiosis or imbalance, with associated altered metabolite profiles, has been associated with increased FA risk, especially in infants delivered by cesarean section, exposed to antibiotics, or lacking certain dietary and environmental exposures. However, findings remain heterogeneous across cohorts, and direct causal mechanisms in humans are not fully established, in part due to logistical challenges and variability in microbiome sequencing and FA definitions. Key gaps include a paucity of mechanistic human studies, limited understanding of the timing and functional impact of dysbiosis, and insufficient standardization of research methodologies. Moreover, although environmental factors such as maternal health, delivery mode, and early-life exposures are linked to microbiome development and FA risk, disentangling their specific contributions remains difficult. Future research focused on standardized, longitudinal studies integrating functional metabolomics and immune profiling to establish causal pathways is critical. Elucidating the precise microbial and metabolic drivers of immune tolerance may enable the development of targeted microbial therapeutics, such as probiotics, dietary modifications, or metabolite supplementation, to reduce FA in at-risk infants. Addressing these gaps is essential to mitigate the rising global burden of pediatric FA.